Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Worki
- PDF / 1,021,161 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 29 Downloads / 125 Views
REVIEW ARTICLE
Questions and Answers on Practical Thrombotic Issues in SARS‑CoV‑2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology Giuseppe Patti1 · Veronica Lio1 · Ilaria Cavallari2 · Felice Gragnano3 · Letizia Riva4 · Paolo Calabrò3 · Giuseppe Di Pasquale4 · Vittorio Pengo5,6 · Andrea Rubboli7 on behalf of the Italian Study Group on Atherosclerosis, Thrombosis, Vascular Biology Accepted: 1 October 2020 © The Author(s) 2020
Abstract In patients with coronavirus disease 2019 (COVID-19), the prevalence of pre-existing cardiovascular diseases is elevated. Moreover, various features, also including pro-thrombotic status, further predispose these patients to increased risk of ischemic cardiovascular events. Thus, the identification of optimal antithrombotic strategies in terms of the risk–benefit ratio and outcome improvement in this setting is crucial. However, debated issues on antithrombotic therapies in patients with COVID-19 are multiple and relevant. In this article, we provide ten questions and answers on risk stratification and antiplatelet/anticoagulant treatments in patients at risk of/with severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection based on the scientific evidence gathered during the pandemic. Since December 2019, when the first cases of interstitial pneumonia were identified in the province of Wuhan, China, the infection due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly involved a large part of the population worldwide, reaching the global pandemic level. National health systems had to implement public health responses to protect their populations and limit viral diffusion. In patients with coronavirus disease 2019 (COVID-19), the high prevalence of cardiovascular comorbidities [1] and the increased incidence of thrombotic events, sustained by multiple factors (Fig. 1), made complex and, * Giuseppe Patti [email protected] 1
Department of Translational Medicine, “Maggiore della Carità” Hospital, University of Eastern Piedmont, Via Solaroli, 17, 28 100 Novara, Italy
2
Campus Bio-Medico University of Rome, Rome, Italy
3
“Sant’Anna and San Sebastiano” Hospital of Caserta, University of Campania “Luigi Vanvitelli”, Naples, Italy
4
“Maggiore” Hospital, Bologna, Italy
5
Campus Biomedico “Pietro d’Abano”, University of Padua, Padua, Italy
6
Fondazione Arianna” On Anticoagulation, Bologna, Italy
7
“S. Maria delle Croci” Hospital, Ravenna, Italy
Key Points Patients with coronavirus disease-19 (COVID-19) have an elevated risk of thrombotic events due to a high prevalence of cardiovascular risk factors, previous cardiovascular diseases and a pro-thrombotic status. In patients with COVID-19 the thrombotic risk outweighs the bleeding risk. Diagnostic and therapeutic approaches for thrombotic events in patients with COVID-19 should take into account the risk of contagion, the baseline risk profile and possible drug interactions.
at the same time, crucial the optimiza
Data Loading...
